Home > > > Report Detail

Global Cancer Monoclonal Antibodies Market Insights, Forecast to 2029

Publisher Name :
Date: 30-May-2023
No. of pages: 77
Inquire Before Buying

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

The global Cancer Monoclonal Antibodies market is projected to grow from US$ 37710 million in 2023 to US$ 63810 million by 2029, at a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period.

Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

Report Includes:

This report presents an overview of global market for Cancer Monoclonal Antibodies, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Cancer Monoclonal Antibodies, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Cancer Monoclonal Antibodies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Monoclonal Antibodies sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Cancer Monoclonal Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Cancer Monoclonal Antibodies sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb and Takeda Pharmaceuticals, etc.

By Company

- F. Hoffmann-La Roche

- Amgen

- Bristol-Myers Squibb

- Takeda Pharmaceuticals

Segment by Type

- Murine Antibodies

- Chimeric and Humanised Antibodies

- Fully Humanized Antibodies

- Others

Segment by Application

- Liver

- Breast

- Blood

- Brain

- Hodgkins and Non-Hodgkins lymphoma

- Colorectal

- Leukaemia

- Others

Segment by Region

- US & Canada

- - U.S.

- - Canada

- China

- Asia (excluding China)

- - Japan

- - South Korea

- - China Taiwan

- Southeast Asia

- - India

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Middle East, Africa, Latin America

- - Brazil

- - Mexico

- - Turkey

- - Israel

- - GCC Countries

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Cancer Monoclonal Antibodies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 3: Detailed analysis of Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.

Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.

Chapter 8: China by type, by application sales and revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.

Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Monoclonal Antibodies sales, revenue, price, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: The main points and conclusions of the report.

Global Cancer Monoclonal Antibodies Market Insights, Forecast to 2029

Table of Contents
1 Study Coverage
1.1 Cancer Monoclonal Antibodies Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Murine Antibodies
1.2.3 Chimeric and Humanised Antibodies
1.2.4 Fully Humanized Antibodies
1.2.5 Others
1.3 Market by Application
1.3.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Liver
1.3.3 Breast
1.3.4 Blood
1.3.5 Brain
1.3.6 Hodgkins and Non-Hodgkins lymphoma
1.3.7 Colorectal
1.3.8 Leukaemia
1.3.9 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cancer Monoclonal Antibodies Sales Estimates and Forecasts 2018-2029
2.2 Global Cancer Monoclonal Antibodies Revenue by Region
2.2.1 Global Cancer Monoclonal Antibodies Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Cancer Monoclonal Antibodies Revenue by Region (2018-2023)
2.2.3 Global Cancer Monoclonal Antibodies Revenue by Region (2024-2029)
2.2.4 Global Cancer Monoclonal Antibodies Revenue Market Share by Region (2018-2029)
2.3 Global Cancer Monoclonal Antibodies Sales Estimates and Forecasts 2018-2029
2.4 Global Cancer Monoclonal Antibodies Sales by Region
2.4.1 Global Cancer Monoclonal Antibodies Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Cancer Monoclonal Antibodies Sales by Region (2018-2023)
2.4.3 Global Cancer Monoclonal Antibodies Sales by Region (2024-2029)
2.4.4 Global Cancer Monoclonal Antibodies Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Cancer Monoclonal Antibodies Sales by Manufacturers
3.1.1 Global Cancer Monoclonal Antibodies Sales by Manufacturers (2018-2023)
3.1.2 Global Cancer Monoclonal Antibodies Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Monoclonal Antibodies in 2022
3.2 Global Cancer Monoclonal Antibodies Revenue by Manufacturers
3.2.1 Global Cancer Monoclonal Antibodies Revenue by Manufacturers (2018-2023)
3.2.2 Global Cancer Monoclonal Antibodies Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibodies Revenue in 2022
3.3 Global Key Players of Cancer Monoclonal Antibodies, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Cancer Monoclonal Antibodies Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cancer Monoclonal Antibodies, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cancer Monoclonal Antibodies, Product Offered and Application
3.8 Global Key Manufacturers of Cancer Monoclonal Antibodies, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Monoclonal Antibodies Sales by Type
4.1.1 Global Cancer Monoclonal Antibodies Historical Sales by Type (2018-2023)
4.1.2 Global Cancer Monoclonal Antibodies Forecasted Sales by Type (2024-2029)
4.1.3 Global Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
4.2 Global Cancer Monoclonal Antibodies Revenue by Type
4.2.1 Global Cancer Monoclonal Antibodies Historical Revenue by Type (2018-2023)
4.2.2 Global Cancer Monoclonal Antibodies Forecasted Revenue by Type (2024-2029)
4.2.3 Global Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
4.3 Global Cancer Monoclonal Antibodies Price by Type
4.3.1 Global Cancer Monoclonal Antibodies Price by Type (2018-2023)
4.3.2 Global Cancer Monoclonal Antibodies Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Cancer Monoclonal Antibodies Sales by Application
5.1.1 Global Cancer Monoclonal Antibodies Historical Sales by Application (2018-2023)
5.1.2 Global Cancer Monoclonal Antibodies Forecasted Sales by Application (2024-2029)
5.1.3 Global Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
5.2 Global Cancer Monoclonal Antibodies Revenue by Application
5.2.1 Global Cancer Monoclonal Antibodies Historical Revenue by Application (2018-2023)
5.2.2 Global Cancer Monoclonal Antibodies Forecasted Revenue by Application (2024-2029)
5.2.3 Global Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
5.3 Global Cancer Monoclonal Antibodies Price by Application
5.3.1 Global Cancer Monoclonal Antibodies Price by Application (2018-2023)
5.3.2 Global Cancer Monoclonal Antibodies Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Cancer Monoclonal Antibodies Market Size by Type
6.1.1 US & Canada Cancer Monoclonal Antibodies Sales by Type (2018-2029)
6.1.2 US & Canada Cancer Monoclonal Antibodies Revenue by Type (2018-2029)
6.2 US & Canada Cancer Monoclonal Antibodies Market Size by Application
6.2.1 US & Canada Cancer Monoclonal Antibodies Sales by Application (2018-2029)
6.2.2 US & Canada Cancer Monoclonal Antibodies Revenue by Application (2018-2029)
6.3 US & Canada Cancer Monoclonal Antibodies Market Size by Country
6.3.1 US & Canada Cancer Monoclonal Antibodies Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Cancer Monoclonal Antibodies Sales by Country (2018-2029)
6.3.3 US & Canada Cancer Monoclonal Antibodies Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Cancer Monoclonal Antibodies Market Size by Type
7.1.1 Europe Cancer Monoclonal Antibodies Sales by Type (2018-2029)
7.1.2 Europe Cancer Monoclonal Antibodies Revenue by Type (2018-2029)
7.2 Europe Cancer Monoclonal Antibodies Market Size by Application
7.2.1 Europe Cancer Monoclonal Antibodies Sales by Application (2018-2029)
7.2.2 Europe Cancer Monoclonal Antibodies Revenue by Application (2018-2029)
7.3 Europe Cancer Monoclonal Antibodies Market Size by Country
7.3.1 Europe Cancer Monoclonal Antibodies Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Cancer Monoclonal Antibodies Sales by Country (2018-2029)
7.3.3 Europe Cancer Monoclonal Antibodies Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Cancer Monoclonal Antibodies Market Size
8.1.1 China Cancer Monoclonal Antibodies Sales (2018-2029)
8.1.2 China Cancer Monoclonal Antibodies Revenue (2018-2029)
8.2 China Cancer Monoclonal Antibodies Market Size by Application
8.2.1 China Cancer Monoclonal Antibodies Sales by Application (2018-2029)
8.2.2 China Cancer Monoclonal Antibodies Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cancer Monoclonal Antibodies Market Size by Type
9.1.1 Asia Cancer Monoclonal Antibodies Sales by Type (2018-2029)
9.1.2 Asia Cancer Monoclonal Antibodies Revenue by Type (2018-2029)
9.2 Asia Cancer Monoclonal Antibodies Market Size by Application
9.2.1 Asia Cancer Monoclonal Antibodies Sales by Application (2018-2029)
9.2.2 Asia Cancer Monoclonal Antibodies Revenue by Application (2018-2029)
9.3 Asia Cancer Monoclonal Antibodies Sales by Region
9.3.1 Asia Cancer Monoclonal Antibodies Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Cancer Monoclonal Antibodies Revenue by Region (2018-2029)
9.3.3 Asia Cancer Monoclonal Antibodies Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Market Size by Type
10.1.1 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Market Size by Application
10.2.1 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Country
10.3.1 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Information
11.1.2 F. Hoffmann-La Roche Overview
11.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 F. Hoffmann-La Roche Recent Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Overview
11.2.3 Amgen Cancer Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Amgen Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Amgen Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb Overview
11.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bristol-Myers Squibb Recent Developments
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Company Information
11.4.2 Takeda Pharmaceuticals Overview
11.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Takeda Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Monoclonal Antibodies Industry Chain Analysis
12.2 Cancer Monoclonal Antibodies Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Monoclonal Antibodies Production Mode & Process
12.4 Cancer Monoclonal Antibodies Sales and Marketing
12.4.1 Cancer Monoclonal Antibodies Sales Channels
12.4.2 Cancer Monoclonal Antibodies Distributors
12.5 Cancer Monoclonal Antibodies Customers
13 Market Dynamics
13.1 Cancer Monoclonal Antibodies Industry Trends
13.2 Cancer Monoclonal Antibodies Market Drivers
13.3 Cancer Monoclonal Antibodies Market Challenges
13.4 Cancer Monoclonal Antibodies Market Restraints
14 Key Findings in The Global Cancer Monoclonal Antibodies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Murine Antibodies
Table 3. Major Manufacturers of Chimeric and Humanised Antibodies
Table 4. Major Manufacturers of Fully Humanized Antibodies
Table 5. Major Manufacturers of Others
Table 6. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Cancer Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Cancer Monoclonal Antibodies Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Cancer Monoclonal Antibodies Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Cancer Monoclonal Antibodies Revenue Market Share by Region (2018-2023)
Table 11. Global Cancer Monoclonal Antibodies Revenue Market Share by Region (2024-2029)
Table 12. Global Cancer Monoclonal Antibodies Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Cancer Monoclonal Antibodies Sales by Region (2018-2023) & (K Units)
Table 14. Global Cancer Monoclonal Antibodies Sales by Region (2024-2029) & (K Units)
Table 15. Global Cancer Monoclonal Antibodies Sales Market Share by Region (2018-2023)
Table 16. Global Cancer Monoclonal Antibodies Sales Market Share by Region (2024-2029)
Table 17. Global Cancer Monoclonal Antibodies Sales by Manufacturers (2018-2023) & (K Units)
Table 18. Global Cancer Monoclonal Antibodies Sales Share by Manufacturers (2018-2023)
Table 19. Global Cancer Monoclonal Antibodies Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2018-2023)
Table 21. Global Key Players of Cancer Monoclonal Antibodies, Industry Ranking, 2021 VS 2022 VS 2023
Table 22. Cancer Monoclonal Antibodies Price by Manufacturers 2018-2023 (USD/Unit)
Table 23. Global Cancer Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Cancer Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibodies as of 2022)
Table 25. Global Key Manufacturers of Cancer Monoclonal Antibodies, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Cancer Monoclonal Antibodies, Product Offered and Application
Table 27. Global Key Manufacturers of Cancer Monoclonal Antibodies, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 30. Global Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 31. Global Cancer Monoclonal Antibodies Sales Share by Type (2018-2023)
Table 32. Global Cancer Monoclonal Antibodies Sales Share by Type (2024-2029)
Table 33. Global Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Cancer Monoclonal Antibodies Revenue Share by Type (2018-2023)
Table 36. Global Cancer Monoclonal Antibodies Revenue Share by Type (2024-2029)
Table 37. Cancer Monoclonal Antibodies Price by Type (2018-2023) & (USD/Unit)
Table 38. Global Cancer Monoclonal Antibodies Price Forecast by Type (2024-2029) & (USD/Unit)
Table 39. Global Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 40. Global Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 41. Global Cancer Monoclonal Antibodies Sales Share by Application (2018-2023)
Table 42. Global Cancer Monoclonal Antibodies Sales Share by Application (2024-2029)
Table 43. Global Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Cancer Monoclonal Antibodies Revenue Share by Application (2018-2023)
Table 46. Global Cancer Monoclonal Antibodies Revenue Share by Application (2024-2029)
Table 47. Cancer Monoclonal Antibodies Price by Application (2018-2023) & (USD/Unit)
Table 48. Global Cancer Monoclonal Antibodies Price Forecast by Application (2024-2029) & (USD/Unit)
Table 49. US & Canada Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 50. US & Canada Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 52. US & Canada Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 54. US & Canada Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 56. US & Canada Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Cancer Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Cancer Monoclonal Antibodies Revenue by Country (2018-2023) & (US$ Million)
Table 59. US & Canada Cancer Monoclonal Antibodies Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Cancer Monoclonal Antibodies Sales by Country (2018-2023) & (K Units)
Table 61. US & Canada Cancer Monoclonal Antibodies Sales by Country (2024-2029) & (K Units)
Table 62. Europe Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 63. Europe Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 64. Europe Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 65. Europe Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 67. Europe Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 68. Europe Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 69. Europe Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Cancer Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Cancer Monoclonal Antibodies Revenue by Country (2018-2023) & (US$ Million)
Table 72. Europe Cancer Monoclonal Antibodies Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Cancer Monoclonal Antibodies Sales by Country (2018-2023) & (K Units)
Table 74. Europe Cancer Monoclonal Antibodies Sales by Country (2024-2029) & (K Units)
Table 75. China Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 76. China Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 77. China Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 78. China Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 80. China Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 81. China Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 82. China Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 84. Asia Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 85. Asia Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 86. Asia Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 88. Asia Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 89. Asia Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 90. Asia Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Cancer Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Cancer Monoclonal Antibodies Revenue by Region (2018-2023) & (US$ Million)
Table 93. Asia Cancer Monoclonal Antibodies Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Cancer Monoclonal Antibodies Sales by Region (2018-2023) & (K Units)
Table 95. Asia Cancer Monoclonal Antibodies Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Type (2018-2023) & (K Units)
Table 97. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Type (2018-2023) & (US$ Million)
Table 99. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Application (2018-2023) & (K Units)
Table 101. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Application (2018-2023) & (US$ Million)
Table 103. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Country (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Country (2018-2023) & (K Units)
Table 108. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales by Country (2024-2029) & (K Units)
Table 109. F. Hoffmann-La Roche Company Information
Table 110. F. Hoffmann-La Roche Description and Major Businesses
Table 111. F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 112. F. Hoffmann-La Roche Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. F. Hoffmann-La Roche Recent Developments
Table 114. Amgen Company Information
Table 115. Amgen Description and Major Businesses
Table 116. Amgen Cancer Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 117. Amgen Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Amgen Recent Developments
Table 119. Bristol-Myers Squibb Company Information
Table 120. Bristol-Myers Squibb Description and Major Businesses
Table 121. Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 122. Bristol-Myers Squibb Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Bristol-Myers Squibb Recent Developments
Table 124. Takeda Pharmaceuticals Company Information
Table 125. Takeda Pharmaceuticals Description and Major Businesses
Table 126. Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 127. Takeda Pharmaceuticals Cancer Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Takeda Pharmaceuticals Recent Developments
Table 129. Key Raw Materials Lists
Table 130. Raw Materials Key Suppliers Lists
Table 131. Cancer Monoclonal Antibodies Distributors List
Table 132. Cancer Monoclonal Antibodies Customers List
Table 133. Cancer Monoclonal Antibodies Market Trends
Table 134. Cancer Monoclonal Antibodies Market Drivers
Table 135. Cancer Monoclonal Antibodies Market Challenges
Table 136. Cancer Monoclonal Antibodies Market Restraints
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Monoclonal Antibodies Product Picture
Figure 2. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Cancer Monoclonal Antibodies Market Share by Type in 2022 & 2029
Figure 4. Murine Antibodies Product Picture
Figure 5. Chimeric and Humanised Antibodies Product Picture
Figure 6. Fully Humanized Antibodies Product Picture
Figure 7. Others Product Picture
Figure 8. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Cancer Monoclonal Antibodies Market Share by Application in 2022 & 2029
Figure 10. Liver
Figure 11. Breast
Figure 12. Blood
Figure 13. Brain
Figure 14. Hodgkins and Non-Hodgkins lymphoma
Figure 15. Colorectal
Figure 16. Leukaemia
Figure 17. Others
Figure 18. Cancer Monoclonal Antibodies Report Years Considered
Figure 19. Global Cancer Monoclonal Antibodies Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 20. Global Cancer Monoclonal Antibodies Revenue 2018-2029 (US$ Million)
Figure 21. Global Cancer Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 22. Global Cancer Monoclonal Antibodies Revenue Market Share by Region (2018-2029)
Figure 23. Global Cancer Monoclonal Antibodies Sales 2018-2029 ((K Units)
Figure 24. Global Cancer Monoclonal Antibodies Sales Market Share by Region (2018-2029)
Figure 25. US & Canada Cancer Monoclonal Antibodies Sales YoY (2018-2029) & (K Units)
Figure 26. US & Canada Cancer Monoclonal Antibodies Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Europe Cancer Monoclonal Antibodies Sales YoY (2018-2029) & (K Units)
Figure 28. Europe Cancer Monoclonal Antibodies Revenue YoY (2018-2029) & (US$ Million)
Figure 29. China Cancer Monoclonal Antibodies Sales YoY (2018-2029) & (K Units)
Figure 30. China Cancer Monoclonal Antibodies Revenue YoY (2018-2029) & (US$ Million)
Figure 31. Asia (excluding China) Cancer Monoclonal Antibodies Sales YoY (2018-2029) & (K Units)
Figure 32. Asia (excluding China) Cancer Monoclonal Antibodies Revenue YoY (2018-2029) & (US$ Million)
Figure 33. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales YoY (2018-2029) & (K Units)
Figure 34. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue YoY (2018-2029) & (US$ Million)
Figure 35. The Cancer Monoclonal Antibodies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 36. The Top 5 and 10 Largest Manufacturers of Cancer Monoclonal Antibodies in the World: Market Share by Cancer Monoclonal Antibodies Revenue in 2022
Figure 37. Global Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 38. Global Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 39. Global Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 40. Global Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 41. Global Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 42. US & Canada Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 43. US & Canada Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 44. US & Canada Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 45. US & Canada Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 46. US & Canada Cancer Monoclonal Antibodies Revenue Share by Country (2018-2029)
Figure 47. US & Canada Cancer Monoclonal Antibodies Sales Share by Country (2018-2029)
Figure 48. U.S. Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 49. Canada Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 50. Europe Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 51. Europe Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 52. Europe Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 53. Europe Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 54. Europe Cancer Monoclonal Antibodies Revenue Share by Country (2018-2029)
Figure 55. Europe Cancer Monoclonal Antibodies Sales Share by Country (2018-2029)
Figure 56. Germany Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 57. France Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 58. U.K. Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 59. Italy Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 60. Russia Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 61. China Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 62. China Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 63. China Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 64. China Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 65. Asia Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 66. Asia Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 67. Asia Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 68. Asia Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 69. Asia Cancer Monoclonal Antibodies Revenue Share by Region (2018-2029)
Figure 70. Asia Cancer Monoclonal Antibodies Sales Share by Region (2018-2029)
Figure 71. Japan Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 72. South Korea Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 73. China Taiwan Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 74. Southeast Asia Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 75. India Cancer Monoclonal Antibodies Revenue (2018-2029) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales Market Share by Type (2018-2029)
Figure 77. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue Market Share by Type (2018-2029)
Figure 78. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Sales Market Share by Application (2018-2029)
Figure 79. Middle East, Africa and Latin America Cancer Monoclonal Antibodies Revenue Market Share by Application (2018-2029)
Figure 80. Middle East, Africa and Latin America
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs